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SUMMARY
Congenital CMV infection is a leading cause of childhood disability. Many children born with 
congenital CMV infection are asymptomatic or have nonspecific symptoms and therefore are 
typically not diagnosed. A strategy of newborn CMV screening could allow for early detection 
and intervention to improve clinical outcomes. Interventions might include antiviral drugs or 
nonpharmaceutical therapies such as speech-language therapy or cochlear implants. Using 
published data from developed countries, we analyzed existing evidence of potential benefit that 
could result from newborn CMV screening. We first estimated the numbers of children with the 
most important CMV-related disabilities (i.e. hearing loss, cognitive deficit, and vision 
impairment), including the age at which the disabilities occur. Then, for each of the disabilities, 
we examined the existing evidence for the effectiveness of various interventions. We concluded 
that there is good evidence of potential benefit from nonpharmaceutical interventions for children 
with delayed hearing loss that occurs by 9 months of age. Similarly, we concluded that there is fair 
evidence of potential benefit from antiviral therapy for children with hearing loss at birth and from 
nonpharmaceutical interventions for children with delayed hearing loss occurring between 9 and 
24 months of age and for children with CMV-related cognitive deficits. We found poor evidence 
of potential benefit for children with delayed hearing loss occurring after 24 months of age and for 
children with vision impairment. Overall, we estimated that in the United States, several thousand 
children with congenital CMV could benefit each year from newborn CMV screening, early 
detection, and interventions. Copyright © 2014 John Wiley & Sons, Ltd.
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Congenital CMV is an important public health problem in pediatric populations (Table 1) 
[1]. It is a leading cause of childhood hearing loss, cognitive deficit, and vision impairment 
[2,3]. The number of children with congenital CMV-related disabilities is similar to or 
greater than the number with better-known conditions such as Down syndrome or spina 
bifida [4]. The economic burden caused by congenital CMV is substantial, as many affected 
children require significant ongoing care and special therapeutic and educational services 
[5]. This has led to calls for improved strategies to reduce the burden of congenital CMV [6–
8], including earlier identification through maternal or newborn screening [9–11], vaccines 
[12,13], behavioral interventions [1,14–16], treatment for infected pregnant women [17,18], 
and treatment of affected infants [19–21]. The objective of this article is to address the 
strategy of newborn CMV screening in developed countries, reviewing the existing evidence 
for potential benefit.
Diagnosis and classification of congenital CMV
Diagnosis of congenital CMV infection based on clinical signs or symptoms alone is not 
definitive. Rather, a definitive diagnosis requires the detection in urine, saliva, or blood of 
CMV via viral culture or of CMV DNA via nucleic acid testing (NAT) within the first 2–3 
weeks after birth [22,23]. Detection of CMV after this age could be due to postnatal 
infection, which has not been associated with birth defects or developmental disabilities 
[24]. Therefore, if hearing loss or cognitive deficit becomes apparent at a later age, a post 
hoc diagnosis of congenital CMV infection generally cannot be made.
Children with congenital CMV infection may be symptomatic or asymptomatic at birth. The 
diagnostic criteria and definition of symptomatic congenital CMV infection vary in the 
literature despite attempts at standardization [25], partly because the clinical signs and 
symptoms (e.g. small for gestational age, petechiae, hemolytic anemia, splenomegaly, 
hepatomegaly, jaundice, pneumonia, microcephaly, and seizures) are not pathognomonic for 
congenital CMV infection and have significant variability ranging from minimal damage to 
fetal death [26]. For the purposes of this article, we classify children as symptomatic if they 
have acute symptoms present at birth. We also describe children who have CNS sequelae 
according to those clinical sequelae at their appearance, but we classify them as 
symptomatic or asymptomatic depending on the presence or absence of acute symptoms at 
birth. Literature definitions of symptomatic congenital CMV frequently include many 
children whose symptoms are sufficiently nonspecific that they generally do not prompt the 
physician to order a CMV test that could lead to a diagnosis of congenital CMV infection. 
Therefore, in the absence of universal newborn CMV screening, not only asymptomatic 
infections but also many symptomatic infections go undiagnosed [3].
Newborn CMV screening
Whether screening for a given condition should become an established health practice 
requires weighing the benefits versus the harms and is usually determined on the basis of a 
number of criteria, such as those described by Wilson and Jungner, and others [27–29]. 
Congenital CMV infection already meets many screening criteria. For example, it is an 
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important public health problem [1] whose incidence is similar to the combined incidence of 
all metabolic or endocrine disorders in the current US core screening panel [9,30]; there is a 
presymptomatic or early symptomatic stage [31]; the test would generally be acceptable to 
the population [32], and much is known of the natural history of the condition [22]. 
Furthermore, there is reason to believe that suitable screening technology, such as CMV 
DNA testing from dried blood spots (DBS), saliva, or urine, will be available soon [33–38]. 
On the other hand, potential harms may include increased parental stress or altered parent–
child relationships from a false positive or true positive screening result (approximately 
three fourths of truly positive children never develop sequelae) [39], inappropriate antiviral 
treatment, or added costs from unnecessary medical visits or tests [40]. One criterion that 
merits greater examination, however, is whether screening can lead to beneficial 
interventions.
Potential benefits of newborn CMV screening
Congenital CMV would be atypical as a newborn screening condition, in that making a 
definitive diagnosis requires testing during the newborn period and cannot generally be 
accomplished at a later age. The exception is when stored biological specimens from the 
newborn period, such as DBS, are available for testing at a later time. However, such 
specimens are often stored for a limited period under less-than-ideal conditions, and 
accessing them has unresolved ethical difficulties in some populations [41]. Therefore, a key 
benefit of newborn CMV screening is that it could ensure a definitive diagnosis, which 
otherwise would be precluded for the majority of infected children.
Several immediate benefits may then follow. A diagnostic odyssey [42–44] could be 
avoided for children with congenital CMV infection who are born with nonspecific 
symptoms or who are asymptomatic at birth but who subsequently develop disabilities, 
preventing some of the difficulties introduced by multiple tests that may have limited 
diagnostic utility [45] (Box 1). Substantial cost savings could be created by avoiding 
unnecessary diagnostic tests, hospital admissions, and therapies that might otherwise occur 
in the quest to diagnose other diseases. Parents would have more confidence that symptoms 
were not the result of genetic causes, clarifying the child's prognosis and the parents’ future 
reproductive decision-making. Furthermore, a definitive diagnosis of congenital CMV 
infection could reduce the considerable stress and anxiety caused by an uncertain diagnosis 
[44]. Conversely, it is possible that additional diagnostic tests, particularly of the CNS, will 
be undertaken in some CMV-infected infants who ultimately do not have neurological 
disease at birth. We have not included this in the analysis as the costs and benefits of such 
investigation cannot be easily quantified, while acknowledging that this will occur in some 
infants who have congenital CMV infection but no clinical disease.
Though the immediate benefits mentioned above are plausible and perhaps likely to occur, 
they are difficult to measure, and therefore, only limited data exist to support them. 
Furthermore, they are less directly related to the child's health and typically are excluded 
from assessments of the value of newborn screening for other conditions. As a result, we 
focused our attention on benefits that directly impact the child's health, are more easily 
measurable, and for which there are more existing data. Specifically, in this review, we 
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assessed the benefits that might accrue from early detection and intervention for children 
who are asymptomatic at birth or whose nonspecific symptoms do not lead to a CMV test 
and definitive diagnosis. Possible interventions might include antiviral drugs or 
nonpharmaceutical therapies such as speech-language therapy, occupational therapy, 
physical therapy, cochlear implants, and/or special education services.
METHODS
We categorized measurable potential benefits according to the most common disabilities 
associated with congenital CMV infection: hearing loss, cognitive deficit (defined as in 
Dollard et al. [46] as intellectual disability or developmental delay), and vision impairment. 
For each disability, we evaluated the evidence of benefit for early detection and intervention 
with nonpharmaceutical interventions or pharmaceutical treatments. For the former, studies 
have not specifically measured outcomes in children known to have congenital CMV 
infection but have measured outcomes in children with disabilities that can be caused by 
congenital CMV infection.
Parameters and assumptions
The parameters we estimated are shown in Table 2. We used these parameters to compute 
the numbers of children with disabilities in Figures 1–3. Rather than reinvent the wheel, we 
based many of the parameter estimates on a recent comprehensive literature review by 
Dollard et al. [46], which used systematic search criteria and explicit inclusion/exclusion 
criteria. In particular, studies were only included if their populations had been identified 
through universal screening at birth (i.e. no patients referred to the study because of 
symptomatic congenital CMV), if they screened at least 800 children in order to identify 
congenitally infected children, if they were from high-income countries, and if they used 
viral culture or PCR detection methods. We also included relevant studies published since 
the Dollard review (2007–2012), which we identified using the same systematic search 
criteria and inclusion/exclusion criteria (e.g. screened populations only) [46]. To estimate 
specific parameters for hearing loss, cognitive deficit, and vision impairment, we manually 
reviewed studies that fit the original search criteria and included all those that reported 
follow-up outcome data for these sequelae (Table 2). As most of the available outcome data 
were from the United States, we computed estimates for each of the three types of disability 
based on live births in the United States, but where necessary, we derived parameters using 
studies from other developed countries where CMV epidemiology is similar to that of the 
United States.
Several parameter estimates (Table 2) require additional explanation. Children born with 
symptomatic congenital CMV who would be tested for CMV because of their presenting 
clinical signs or symptoms are referred to herein as “diagnosed clinically.” We presumed 
these children would derive no additional benefit from newborn CMV screening, except 
perhaps for the very limited benefit of a more immediate diagnosis. We estimated the 
proportion of symptomatic children diagnosed clinically by using studies that identified 
children through active surveillance in well-defined populations in the absence of newborn 
CMV screening. For each study, we divided the observed number of symptomatic 
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congenital CMV cases by the expected number of symptomatic cases derived using the 
appropriate parameters in Table 2. The proportions were 3.8% [47], 12.5% [3], 15.7% [48], 
and 25.0% [49]. Active clinical surveillance misses some symptomatic cases correctly 
diagnosed by health care providers; hence, we assigned our parameter the highest percentage 
(i.e. 25%) in order to be conservative. We also made an alternative calculation of this 
parameter for comparison, in which we assumed that children who had only one CMV-
associated symptom (e.g. Apgar score <7, small for gestational age, and petechiae) would 
not be diagnosed clinically with congenital CMV infection in the absence of screening, 
whereas those with more than one CMV-associated symptom would be diagnosed clinically 
[50]. This calculation from a screened population showed that 13% of newborns with 
symptomatic congenital CMV had more than one symptom. Using health insurance claims 
data as another source of comparison, we found that few newborns (0–10%) who have 
CMV-associated symptoms are tested for CMV [51], and therefore, few would be 
diagnosed.
For our estimate of the percentage of children born with symptomatic congenital CMV 
infection and who have cognitive deficits, we assumed that only those with additional CNS 
sequelae such as hearing loss or motor disability would be diagnosed clinically, whereas 
those with isolated cognitive deficits would not. We made this assumption because isolated 
cognitive deficit is not typically diagnosed until months or years after birth [52], at which 
time it is usually too late for a definitive diagnosis of congenital CMV infection.
Finally, for the various groups of children whose outcomes might be affected by newborn 
CMV screening, we categorized the quality of evidence for potential benefit as good, fair, or 
poor, where good included consistent evidence from well-designed studies; fair included 
evidence limited by the number, quality, or consistency of the individual studies; and poor 
included evidence limited by the number or power of studies, flaws in their design or 
conduct, or gaps in the chain of evidence [53].
RESULTS
Hearing loss
The epidemiology of CMV-related hearing loss is shown in Figure 1. On the basis of the 
parameter values calculated in Table 2, we estimated that each year in the United States, 
approximately 25,000 children are born with congenital CMV infection. We divided the 
children into groups based on whether they were symptomatic at birth and diagnosed 
clinically (i.e. because their signs and symptoms led to a CMV test), were symptomatic at 
birth and not diagnosed clinically, or were asymptomatic at birth. We further divided the 
latter two groups into their various hearing-related outcomes. Hearing loss can occur in any 
of these groups, sometimes being present at birth and other times developing over months or 
years.
Nonpharmaceutical interventions—Aside from the indirect potential benefits 
mentioned earlier (avoidance of diagnostic odyssey, parental peace of mind, physician 
awareness of diagnosis, etc.), we concluded that children with hearing loss at birth would 
derive no additional direct benefit from newborn CMV screening and nonpharmaceutical 
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interventions, because these children would presumably be detected through universal 
newborn hearing screening. Because newborn hearing screening misses some children born 
with hearing loss, it is possible that having a congenital CMV diagnosis would lead to 
higher clinical suspicion and more careful monitoring for hearing loss, thus increasing 
opportunities for early intervention. However, we did not include this as a direct benefit 
because there are insufficient data to quantify it.
For children with delayed congenital CMV-associated hearing loss that occurs by 9 months 
of age, we concluded that there is good evidence of benefit from newborn CMV screening 
(Figure 1). In a landmark study assessing the benefit of universal newborn hearing 
screening, Kennedy et al. [54] demonstrated that children diagnosed with hearing loss by 9 
months of age were significantly more likely to develop better receptive and expressive 
language than children diagnosed after 9 months of age.
We next considered children whose delayed hearing loss occurs between 9 and 24 months of 
age because they would, on average, still be diagnosed earlier with newborn CMV screening 
than they would in its absence. Prior to universal newborn hearing screening, the average 
age at diagnosis of hearing loss was approximately 24–30 months [55,56]. For these 
children, we concluded that newborn CMV screening has fair evidence of benefit from 
nonpharmaceutical intervention because a number of studies (summarized by Nelson et al. 
[57]) found evidence of better receptive and expressive language among children whose 
hearing loss was identified earlier rather than later, but these studies had more 
methodological limitations than Kennedy et al. [54]. The nonpharmaceutical interventions 
varied across the studies, but they all could be classified as early intervention services, 
which may include speech-language therapy, occupational therapy, assistive technology 
devices, and so on.
Finally, we considered the children with congenital CMV infection whose delayed hearing 
loss occurs between 24 and 72 months of age (Figure 1) [31]. If they were screened for 
congenital CMV at birth, they might receive closer clinical follow-up and an earlier 
diagnosis of hearing loss; although moderate to profound hearing loss is frequently 
recognized and treated before school age, mild or unilateral hearing loss can remain 
undiagnosed for years [58]. An earlier diagnosis of hearing loss may be beneficial even 
among children between 24 and 72 months of age, because the many benefits derived from 
cochlear implants are greater for children with a shorter time from hearing loss until 
implantation [59–63]. Therefore, we concluded that children whose onset of hearing loss 
happens between 24 and 72 months of age may receive limited benefit, but the quality of 
evidence remains poor.
Pharmaceutical interventions—Treatment with IV ganciclovir was shown in a 
randomized controlled trial (RCT) to reduce the progression of hearing loss in children with 
symptomatic congenital CMV who have CNS manifestations [20]. However, the subset of 
symptomatic children who are diagnosed clinically and who meet the trial eligibility 
requirements (e.g. CNS manifestations) may benefit from pharmaceutical treatment, but 
newborn screening would not provide an added benefit because they are already identified in 
the absence of screening. The subset of symptomatic newborns who are not diagnosed 
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clinically but who have hearing loss may also benefit from pharmaceutical treatment 
because they fit the trial criteria (e.g. clinically apparent disease and hearing deficit). For 
them, newborn screening would provide a diagnosis that would make them potential 
candidates for such treatment, and thus, we concluded that they have fair evidence of benefit 
from newborn CMV screening. Newborns who are asymptomatic at birth but who have 
hearing loss might benefit from pharmaceutical treatment, but the benefit is less certain 
because this category of children was excluded from the trial. Ongoing trials of 
valganciclovir are looking for benefit in this subgroup (clinicaltrials.gov, study identifiers 
NCT02005822 and NCT01649869), but for the time being, we concluded that they have 
poor evidence of benefit from newborn screening.
Cognitive deficits
Estimates of the frequency of cognitive deficit (i.e. intellectual disability or developmental 
delay) among children with congenital CMV infection are shown in Figure 2. Congenital 
CMV-related cognitive deficits most likely have a natural history that is similar to other 
neurodevelopmental disorders where the condition is present at birth, but recognition by 
providers and parents is often delayed until the first or second year of life. Frequently, a 
confirmatory diagnosis may not occur until the child is even older [52,64]. Among children 
with symptomatic congenital CMV who have cognitive deficits, some will have severe 
manifestations at birth that would likely lead to a CMV test and subsequent diagnosis. 
However, some are likely to be diagnosed only through newborn CMV screening.
The occurrence of cognitive deficits is clearly higher among children with symptomatic 
congenital CMV infection (Figure 2) than in the general population of children. It is less 
clear whether children born with asymptomatic congenital CMV infection have a higher 
prevalence of cognitive deficits than the general population of children. On the basis of a 
combined population of 469 asymptomatic children, we found a prevalence of cognitive 
deficit of 4.7% (Table 2). A recent summary estimate of cognitive deficit among the general 
population was only slightly lower, at 3.8% [65], but this would include some children with 
congenital CMV-induced deficits. Some studies have reported a moderately lower mean IQ 
among children with asymptomatic congenital CMV infection compared with controls but 
only among children younger than 6 years of age [66–70]. Studies of children older than 6 
years have not found significant differences in mean IQ [67,68,71–73].
Nonpharmaceutical interventions—Children with CMV-associated cognitive deficits 
(albeit unknown at birth) who screen positive for congenital CMV infection could be 
considered to be at risk for poor developmental outcomes. Some studies indicate that 
children with an identified at-risk condition or a clinical diagnosis have an earlier age of first 
concern from parents or caregivers, an earlier development of an Individual Family Service 
Program, and an earlier receipt of early intervention services [74–77]. Other studies indicate 
that children with risk factors for cognitive deficits are more likely to be screened for 
developmental delays and that screened children are more likely to be referred for and 
receive early intervention services [76,78]. Importantly, children with cognitive deficits who 
receive early intervention services have better outcomes than similar children who do not 
receive such services [79–84]. On the basis of these studies, we concluded that there is fair 
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evidence of benefit related to newborn CMV screening for children with CMV-associated 
cognitive benefits.
Pharmaceutical interventions—In the same RCT of children with symptomatic 
congenital CMV and CNS involvement [20], those who received 6 weeks of iv ganciclovir 
treatment had better developmental outcomes than children who received no treatment [85]. 
It is unlikely, however, that newborn CMV screening would lead to added benefit for these 
children because they most likely would be diagnosed because of their clinical presentation. 
For the children who would only be detected early if newborn screening were in place (i.e. 
children with cognitive deficit who are asymptomatic or who have nonspecific symptoms), 
no evidence is available to assess whether they would experience improved developmental 
outcomes because of antiviral drug treatment.
Vision impairment
Although less common than hearing loss or cognitive deficit, vision impairment is another 
significant disability that can be caused by congenital CMV infection. Vision impairment 
may be present at birth or it may occasionally be delayed [86,87]. Vision impairment 
typically occurs among children who are symptomatic at birth, but in some studies, it has 
been reported in children who were asymptomatic at birth [86,88–90]. Estimates of the 
epidemiology of congenital CMV-related vision impairment are shown in Figure 3.
Nonpharmaceutical interventions—Although CMV-related blindness is likely to be 
identified early, partial vision impairment may be less apparent. Such vision impairment 
may not be detected because approximately one third of children aged 3–5 years do not 
receive vision testing [91,92]. For children whose vision impairment is diagnosed, there is 
some evidence that developmental outcomes can be improved through training of visual 
functions [93,94]. Therefore, if newborn CMV screening leads to better follow-up and more 
vision screening, it could also lead to early intervention for vision impairment and thus 
contribute to improved outcomes among these children. Because of insufficient data, we 
concluded that the evidence for newborn CMV screening leading to better outcomes for 
children with CMV-related vision impairment remains poor (Figure 3).
Pharmaceutical interventions—Little evidence is available on the effect of antiviral 
treatment on vision impairment. The previously cited RCT did not measure vision 
impairment as an endpoint [20], and even if it had, the enrolled children would have been 
diagnosed with congenital CMV in the absence of screening. One case report found that 
intravitreal injections of ganciclovir led to regression of ocular disease in a child with 
congenital CMV infection [95].
DISCUSSION
On the basis of available evidence, we conclude that each year in the United States as many 
as several thousand children with congenital CMV could benefit from newborn CMV 
screening, early detection, and intervention. These analyses may apply to other developed 
countries as well, suggesting that many more thousands of infected children could benefit 
worldwide. None of the benefits of newborn CMV screening will occur without adequate 
Cannon et al. Page 8













follow-up for early detection and intervention. Therefore, newborn screening represents the 
potential for benefit that can accrue as a result of integration of screening for CMV into the 
newborn screening program.
To provide some perspective, each year in the United States, approximately 6400 children 
with potential adverse health conditions are detected through the newborn DBS screening 
program [30], and approximately 5100 children with hearing loss are detected through 
newborn hearing screening programs (Figure 4) [96]. The type and magnitude of the benefit 
that can result for these children is variable, ranging from the prevention of death or 
cognitive deficit to the improvement of developmental or educational outcomes. The 
potential screening benefits for congenital CMV would not include the prevention of death 
or severe disability but would be similar to the types of benefits associated with the newborn 
hearing screening program, with improved outcomes through early detection and 
intervention.
The potential benefits of newborn CMV screening would be maximized by monitoring and 
screening children identified with congenital CMV infection in order to detect hearing loss, 
cognitive deficit, and vision impairment as early as possible. Some practical guidelines for a 
follow-up and monitoring schedule have been proposed and would include confirmation of 
screening results, tests to aid the prognosis (e.g. CMV viral load), regular audiologic, 
neurodevelopmental, and ophthalmologic assessments, as well as provision of family 
support [97]. The US Joint Committee on Infant Hearing also provides specific guidance for 
follow-up of children with risk conditions such as congenital CMV infection [98].
The evidence of potential benefit for newborn CMV screening is limited by the scarcity of 
data to generate estimates for some parameters. As a result, we were unable to generate a 
precise estimate of potential benefit, and the numbers we provide should be considered 
approximate and provisional until more data become available. Furthermore, the numbers of 
children with each disability who might benefit from screening cannot be added together, 
because some children are affected by multiple disabilities [99]. In addition, not every child 
will benefit from the interventions, because neither the nonpharmaceutical nor the 
pharmaceutical interventions are 100% effective. For example, in the RCT, ganciclovir did 
not lead to improved hearing, although it did appear to limit hearing deterioration, and its 
efficacy remains controversial because nearly 60% of the trial participants did not have 
evaluable outcomes. Nevertheless, on the basis of our analyses, we conclude that newborn 
CMV screening has the potential to provide a meaningful benefit to at least as many children 
as are already helped by existing newborn screening programs for some other conditions.
Another limitation of our analyses was the subjective grading of the potential benefits. We 
based our grading on a scale used previously by the US Preventive Services Task Force that 
seemed to best fit this type of evidence review [53]. The grading was complicated by the 
different medical conditions we evaluated, the different types of evidence, the different ways 
of linking the evidence, and the absence of intervention studies in children known to have 
congenital CMV. Therefore, we presented our subjective judgment of the totality of the 
evidence, while providing readers with the supporting data on which we based these 
judgments.
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We did not attempt to address targeted newborn CMV screening, although such an approach 
might be worth pursuing. For example, rather than screen all newborns for CMV, screening 
could be limited to those children having particular risk factors, such as being small for 
gestational age or having failed their initial hearing screen. Targeted CMV screening would 
benefit fewer children, but it may also have fewer negative effects and could possibly be 
more cost-effective than universal screening.
Our review clearly highlights some deficiencies in research on congenital CMV. Relatively 
few studies have been carried out on longitudinal outcomes of congenital CMV infection, 
undoubtedly because of the substantial resources required to screen tens of thousands of 
children and then follow hundreds of them for years. In addition, few treatment options exist 
for infected mothers or children, and no effective vaccine is imminent. The high disease 
burden that we chronicled suggests the importance of better epidemiology and better 
treatment and prevention options.
Finally, we examined only the evidence of benefit and did not attempt to provide a complete 
accounting of the value of newborn CMV screening. Such analyses can be found elsewhere 
[8,9,100]. As with all medical screening programs, potential benefits need to be weighed 
against potential harms [101]. The costs of newborn CMV screening need to be evaluated, 
and appropriate screening tests need to be available. Because newborn CMV screening 
might be considered a public health service rather than public health emergency [102], 
prenatal or postnatal counseling and consent may be more ethical than mandatory screening 
[103,104]. Nevertheless, the evidence for potential benefits to thousands of children each 
year in the United States alone should lead to careful consideration of newborn CMV 
screening.
Abbreviations used
NAT nucleic acid testing
DBS dried blood spots
RCT randomized controlled trial
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Box 1. Case example of diagnostic odyssey
Ms. SI was born preterm (34 weeks gestation), with weight <10th centile, and breast-fed 
normally, with normal neonatal hearing screening. She attained her developmental 
milestones until 4 months of age when she presented in winter with severe, bilateral 
pneumonitis, and minor hepatosplenomegaly. She was admitted via emergency to 
intensive care (CICU), was ventilated, and treated with antibiotics for community 
acquired pneumonia and oseltamivir for possible influenza. The diagnosis was made 
from chlamydia IgM seropositivity and possible influenza from single high titer serology. 
Her respiratory status improved over the 8-day CICU and ward admission, and she was 
discharged 2 weeks following admission. At home, Ms. SI was feeding poorly, and failed 
to gain weight, with continuing minor hepatosplenomegaly and occasional lack of 
response to some auditory stimuli. She was readmitted at 5 months of age with 
deteriorating respiratory status, required continuous positive airway pressure support, and 
investigations showed chlamydia IgG+/IgM+, mycoplasma IgM+, and nucleic acid tests 
(NAT) negative for influenza A/B, RSV, parainfluenza 1/2/3, and adenovirus; she was 
restarted on antibiotics. Over the following week, she required intubation and ventilation 
by high frequency oscillation. She developed bilateral pneumothoraces requiring 
intercostal drainage and intravenous support via subclavian lines. Additional testing 
demonstrated CMV NAT positivity on bronchial washings and CMV IgG+/IgM+. She 
received intravenous ganciclovir for a total of 6 weeks and CMV immunoglobulin on two 
occasions. Ms. SI's Guthrie (neonatal blood screening) card was CMV NAT positive, 
diagnostic of congenital CMV.
The lack of initial diagnosis of CMV pneumonitis resulted in inappropriate antibiotic 
therapy; missed opportunities for early antiviral therapy; subsequent development of 
chronic lung disease, most likely on the basis of untreated congenital CMV; and on final 
discharge, she required omeprazole and prokinetic doses of erythromycin for reflux and 
increased work of breathing. She could not be assessed for hearing loss without 
anesthesia, because of the late diagnosis, as she had two attempted brainstem auditory 
evoked response (BAER) tests without sedation, which were unsuccessful because of her 
intolerance of the procedure. Sedated BAER testing later was abnormal, showing normal 
tympanograms bilaterally, bilaterally absent transient evoked otoacoustic emissions 
consistent with poor outer hair cell function, and air conduction BAER showing 
moderate hearing loss in the left ear. She had no enhanced speech therapy initially, 
although hearing loss was subsequently proven. By 6 years of age, she had moderate left 
hearing loss, mild neurodevelopmental delay, improving respiratory function, and was 
otherwise well. Her parents had never heard of CMV prior to her diagnosis, and they 
were diagnosed with clinical anxiety during counseling for how to care for a child with 
chronic lung disease.
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Estimates of USA annual congenital CMV-related hearing loss, including numbers of 
children with hearing loss who would potentially benefit from newborn CMV screening. 
Boxes denoting children who would potentially benefit are shaded from lighter to darker 
according to a subjective rating of the increasing strength of evidence. For some, the benefit 
would be due to pharmaceutical treatment (i.e. those with hearing loss at birth); whereas, for 
the others the benefit would be due to nonpharmaceutical interventions. Because children 
can experience multiple disabilities, the number of children in Figures 1–3 who would 
potentially benefit from screening cannot necessarily be added together
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Estimates of US annual congenital CMV-related cognitive deficit, including numbers of 
children with cognitive deficit who would potentially benefit from newborn CMV screening. 
Boxes denoting children who would potentially benefit are shaded from lighter to darker 
according to a subjective rating of the increasing strength of evidence. Because children can 
experience multiple disabilities, the number of children in Figures 1–3 who would 
potentially benefit from screening cannot necessarily be added together
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Estimates of US annual congenital CMV-related vision impairment, including numbers of 
children with vision impairment who would potentially benefit from newborn CMV 
screening. Boxes denoting children who would potentially benefit are shaded from lighter to 
darker according to a subjective rating of the increasing strength of evidence. Because 
children can experience multiple disabilities, the number of children in Figures 1–3 who 
would potentially benefit from screening cannot necessarily be added together
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Annual cases for conditions that make up the core US newborn screening panel [30], along 
with estimates of annual US cases of congenital CMV-related disabilities. There is some 
overlap among the children with hearing loss and the children with congenital CMV-related 
disabilities. However, children in these two groups may not be strictly comparable because 
newborn hearing screening typically uses >40 dB as a cutoff for hearing loss, whereas the 
congenital CMV literature sometimes uses a cutoff as low as >20 dB
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Table 1
Estimates of children with congenital CMV-related disability: examples from Australia, England and Wales, 
and the United States
Annual number of: Australia (population 
~22 million)













Congenital CMV infections (0.6%)
a 1,780 4,254 25,488
    Symptomatic at birth (12.8%)
a 228 544 3,262




    Asymptomatic at birth (87.2%)
a 1,552 3,710 22,226












From Office for National Statistics [105].
e
From Martin et al.[106].
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